[1]
|
[1] Chan, S.L., Brown, C.A., and Morgan, N.G. (1993) Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. Eur J Pharmacol, 230(3), 375-8.
|
[2]
|
[2] Schulz, A. and Hasselblatt, A. (1989) An insulin-releasing property of imidazoline derivatives is not limited to compounds that block alpha-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol, 340, 321-7.
|
[3]
|
[3] Berdeu, D., Puech, R., Ribes, G., Loubatieres-Mariani, M.M., and Bertrand, G. (1997) Antazoline increases insu-lin secretion and improves glucose tolerance in rats and dogs. Eur J Pharmacol, 324, 233.
|
[4]
|
[4] Pele-Tounian, A., Chan, S.L., Rondu, F., Le Bihan, G., Giroix, M.H., Lamouri, A., Touboul, E., Pfeiffer, B., Manechez, D., Renard, P., Guardiola-Lemaitre, B., God-froid, J.J., Penicaud, L., Morgan N.G., and Ktorza A. (1999) Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. Eur J Pharmacol, 377, 81-87.
|
[5]
|
[5] Wang, X., Rondu, F., Lamouri, A., Dokhan, R., Marc, S., Touboul, E., Pfeiffer, B., Manechez D., Renard, P., Guar-diola-Lemaitre, B., Godfroid, J.J., Ktorza, A., and Peni-caud, L. (1996) Effect of S-21663 (PMS 812), an imida-zoline derivative, on glucose tolerance and insulin secre-tion in a rat model of type II diabetes. J Pharmacol Exp Ther, 278, 82-89.
|
[6]
|
[6] Williams, C.A., Shih, M.F., and Taberner, P.V. (2000) Effect of acute and sub-chronic administration of the imidazoline compound S22068 on in vivo glucose and insulin responses in normal lean CBA/Ca mice. Gen. Pharmacol., 34, 183-91.
|
[7]
|
[7] Efendic, S., Efanov, A.M., Berggren, P.O., and Zaitsev, S.V. (2002) Two generations of insulinotropic imidazoline compounds. Diabetes, 51 (3), S448-S547.
|
[8]
|
[8] Efanov, A.M., Zaitsev, S.V., Mest, H.J., Raap, A., Appel-skog, I.B., Larsson, O., Berggren, P.O., and Efendic, S. (2001) The novel imidazoline compound BL11282 po-tentiates glucose-induced insulin secretion in pancreatic beta-cells in the absence of modulation of KATP channel activity. Diabetes, 50, 797-802.
|
[9]
|
[9] Proks, P. and Ashcroft, F.M. (1997) Phentolamine block of KATP channels is mediated by Kir6.2. Proc Natl Acad Sci USA, 94, 1716-20.
|
[10]
|
[10] Morgan, N.G., Chan, S.L., Mourtada, M., Monks, L.K., and Ramsden, C.A. (1999) Imidazolines and pancreatic hormone secretion. Ann N Y Acad Sci, 881, 217-28.
|
[11]
|
[11] Farret, A., Lugo-Garcia, L., Galtier, F., Gross, R., and Petit, P. (2005) Pharmacological interventions that di-rectly stimulate or modulate insulin secretion from pan-creatic beta-cell: Implications for the treatment of type 2 diabetes. Fundam Clin Pharmacol, 19, 647-656.
|
[12]
|
[12] Mourtada, M., Smith, S.A., and Morgan, N.G. (1998) Effector systems involved in the insulin secretory re-sponses to efaroxan and RX871024 in rat islets of Langerhans. Eur J Pharmacol, 350, 251-8.
|
[13]
|
[13] Rustenbeck, I., Leupolt, L., Kowalewski, R., and Hassel-blatt, A. (1999) Heterogeneous characteristics of imida-zoline-induced insulin secretion. Naunyn Schmiedebergs Arch Pharmacol, 359, 235-42.
|
[14]
|
[14] Mourtada, M., Brown, C.A., Smith, S.A., Piercy, V., Chan, S.L., and Morgan, N.G. (1997) Interactions between imi-dazoline compounds and sulphonylureas in the regulation of insulin secretion. Br J Pharmacol, 121, 799-805.
|
[15]
|
[15] Berdeu, D., Gross, R., Puech, R., Loubatieres-Mariani, M.M., and Bertrand, G. (1995) Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur J Pharmacol, 275, 91-8.
|
[16]
|
[16] Zaitsev, S.V., Efanov, A.M., Raap, A., Efanova, I.B., Schloos, J., Steckel-Hamann, B., Larsson, O., Ostenson, C.G., Berggren, P.O., Mest, H.J., and Efendic, S. (1999) Different modes of action of the imidazoline compound RX871024 in pancreatic beta-cells: Blocking of K+ channels, mobilization of Ca2+ from endoplasmic reticu-lum, and interaction with exocytotic machinery. Ann N Y Acad Sci, 881, 241-52.
|
[17]
|
[17] Boronat, M.A., Olmos, G., Miller, D.D., Patil, P.N., and Garcia-Sevilla, J.A. (1998) Isothiocyanatobenzyl imida-zoline is an alkylating agent for I2-imidazoline binding sites in rat and rabbit tissues. Naunyn Schmiedebergs Arch Pharmacol, 357, 351-57.
|
[18]
|
[18] Chan, S.L., Brown, C.A., Scarpello, K.E., and Morgan, N.G. (1994) The imidazoline site involved in control of insulin secretion: Characteristics that distinguish it from I1- and I2-sites. Br J Pharmacol, 112, 1065-70.
|
[19]
|
[19] Le Brigand, L., Virsolvy, A., Manechez, D., Godfroid, J.J., Guardiola-Lemaitre, B., Gribble, F.M., Ashcroft, F.M., and Bataille, D. (1999) In vitro mechanism of action on insulin release of S-22068: A new putative antidiabetic compound. Br J Pharmacol, 128, 1021-6.
|
[20]
|
[20] Cooper, E.J., Hudson, A.L., Parker, C.A., and Morgan, N.G. (2003) Effects of the beta-carbolines, harmane and pinoline: On insulin secretion from isolated human islets of Langerhans. Eur J Pharmacol, 482, 189-96.
|
[21]
|
[21] Mayer, G. and Taberner, P.V. (2002) Effects of the imi-dazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. Eur J Pharmacol, 454, 95-102.
|
[22]
|
[22] Ernsberger, P. (1992) Heterogeneity of imidazoline bind-ing sites: Proposed I1 and I2 subtypes. Fund Clin Phar-macol., 6(1), 55S.
|
[23]
|
[23] Coupry, I., Podevin, R.A., Dausse, J.P., and Parini, A. (1987) Evidence for imidazoline binding sites in baso-lateral membranes from rabbit kidney. Biochem Biophys Res Commun, 147, 55-60.
|
[24]
|
[24] Hudson, A.L, Husbands, S., Lewis, J.W., and Nutt, D.J. (1994) Affinity and selectivity of BU224 and BU239 for rabbit brain non-adrenoceptor idazoxan binding sites (I2-sites). Br J Pharmacol, 112, (Proceedings Suppl), 320.
|
[25]
|
[25] Jou, S.B., Liu, I.M., and Cheng, J.T. (2004) Activation of imidazoline receptor by agmatine to lower plasma glucose in streptozotocin-induced diabetic rats. Neurosci Lett, 358, 111-4.
|
[26]
|
[26] MacInnes, N. and Handley, S.L. (2002) Characterization of the discriminable stimulus produced by 2-BFI: Effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine, and ibogaine. Br J Pharmacol, 135, 1227-34.
|
[27]
|
[27] Nutt, D.J., French, N., Handley, S., Hudson, A., Husbands, S., Jackson, H., Jordan, S., Lalies, M.D., Lewis, J., Lione, L., et al. (1995) Functional studies of specific imidazoline-2 receptor ligands. Ann N Y Acad Sci, 763, 125-39.
|
[28]
|
[28] García-Barrado, M.J., Sancho, C., Iglesias-Osma, M.C., and Moratinos, J. (2001) Effects of verapamil and el-godipine on isoprenaline-induced metabolic responses in rabbits. Eur J Pharmacol., 415, 105-115.
|
[29]
|
[29] Moratinos, J., Carpene, C., De Pablos, I., and Reverte, M. (1988) Role of alpha 1- and alpha 2-adrenoceptors in catecholamine-induced hyperglycaemia, lipolysis and insulin secretion in conscious fasted rabbits. Br J Phar-macol, 94, 299-310.
|
[30]
|
[30] Chan, S.L., Dunne, M.J., Stillings M.R., and Morgan, N.G. (1991) The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells. Eur J Pharmacol, 204, 41-8.
|
[31]
|
[31] Gembal, M., Gilon, P., and Henquin, J.C. (1992) Evidence that glucose can control insulin release independently from its action on ATP-sensitive K+ channels in mouse B cells. J Clin Invest, 89, 1288-95.
|
[32]
|
[32] Cuchillo-Ibanez, I., Lejen, T., Albillos, A., Rose, S.D., Olivares, R., Villarroya, M., et al. (2004) Mitochondrial calcium sequestration and protein kinase C cooperate in the regulation of cortical F-actin disassembly and secre-tion in bovine chromaffin cells. J Physiol, 560, 63-76.
|
[33]
|
[33] Henquin, J.C. (2004) Pathways in beta-cell stimulus- secretion coupling as targets for therapeutic insulin se-cretagogues. Diabetes, 53 (3), S48-S58.
|
[34]
|
[34] Zaitsev, S.V., Efanov, A.M., Efanova, I.B., Larsson, O., Ostenson, C.G., Gold, G., Berggren, P.O., and Efendic, S. (1996) Imidazoline compounds stimulate insulin release by inhibition of KATP channels and interaction with the exocytotic machinery. Diabetes, 45, 1610-1618.
|
[35]
|
[35] Serban, D.N., Serban, I.L., and Nechifor, M. (2004) Ida-zoxan effects upon contractile activity in the rat aorta are related to alpha adrenoceptors and L-type channels. Fundan Clin Pharmacol, 18, 635-41.
|
[36]
|
[36] Malaisse, W.J. and Moratinos, J. (1986) Are pancreatic beta-cells equipped with alpha-1 adrenoceptors? IRCS Med Sci, 1194-1195.
|
[37]
|
[37] Ugedo, L., Pineda, J., Ruiz-Ortega, J.A., and Martin-Ruiz, R. (1998) Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: An in vivo and in vitro electrophysiological study. Br J Pharmacol, 125, 1685-1694.
|
[38]
|
[38] Efanov, A.M., Zaitsev, S.V., Efanova, I.B., Zhu, S., Os-tenson, C.G., Berggren, .PO., and Efendic, S. (1998) Signalling and sites of interaction for RX-871024 and sulfonylurea in the stimulation of insulin release. Am J Physiol, 274, E751-E757.
|
[39]
|
[39] Mourtada, M., Chan, S.L., Smith, S.A., and Morgan, N.G. (1999) Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in iso-lated rat pancreatic islets. Br J Pharmacol, 127, 1279- 1287.
|
[40]
|
[40] Chan, S.L., Mourtada, M., and Morgan, N.G. (2001) Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. Diabetes, 50, 340-347.
|
[41]
|
[41] Bleck, C., Wienbergen, A., and Rustenbeck, I. (2005) Essential role of the imidazoline moiety in the insulino-tropic effect but not the KATP channel-blocking effect of imidazolines: A comparison of the effects of efaroxan and its imidazole analogue, KU14R. Diabetologia, 48, 2567-75.
|
[42]
|
[42] Bour, S., Iglesias-Osma, M.C., Marti, L., Duro, P., Gar-cia-Barrado, M.J., Pastor, M.F., Prevot, D., Visentin, V., Valet, P., Moratinos, J., and Carpene, C. (2006) The imi-dazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes. Eur J Pharmacol, 552, 20-30.
|
[43]
|
[43] Iglesias-Osma, M.C., Garcia-Barrado, M.J., Visentin, V., Pastor-Mansilla, M.F., Bour, S., Prevot, D., Valet, P., Moratinos, J., and Carpene, C. (2004) Benzylamine ex-hibits insulin-like effects on glucose disposal, glucose transport, and fat cell lipolysis in rabbits and diabetic mice. J Pharmacol Exp Ther, 309, 1020-1028.
|
[44]
|
[44] Kimura, A., Tyacke, R.J., Minchin, M.C., Nutt, D.J., and Hudson, A.L. (2003) Identification of an I(2) binding protein from rabbit brain. Ann N Y Acad Sci, 1009, 364-366.
|
[45]
|
[45] Paterson, L.M., Robinson, E.S., Nutt, D.J., and Hudson, A.L. (2003) In vivo estimation of imidazoline(2) binding site turnover. Ann N Y Acad Sci, 1009, 367-370.
|
[46]
|
[46] Dickinson, K., North, T.J., and Jones, R.B. (1999) BTS 67 582 may mediate insulin secretion via the putative pancre-atic islet imidazoline receptor. Br J Pharmacol, 126, 133.
|
[47]
|
[47] Page, T.B.C.J. (1997) Glucose-lowering effect of BTS 67 582. Br J Pharmacol, 122, 1464-8.
|
[48]
|
[48] Tesson, F., Limon-Boulez, I., Urban, P., Puype, M., Vandekerckhove, J., Coupry, I., Pompon, D., and Parini, A. (1995) Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem, 270, 9856-61.
|
[49]
|
[49] Marti, L., Morin, N., Enrique-Tarancon, G., Prevot, D., Lafontan, M., Testar, X., Zorzano, A., and Carpene, C. (1998) Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase- dependent generation of hydrogen peroxide. J Pharmacol Exp Ther, 285, 342-9.
|
[50]
|
[50] Portillo, M., Reverte, M., Langin, D., Senard, J.M., Tran, M.A., Berlan, M., and Montastruc, J.L. (1991) Effect of a 7-day treatment with idazoxan and its 2-methoxy deriva-tive RX 821002 [correction of RX 821001] on alpha 2-adrenoceptors and non-adrenoceptor idazoxan binding sites in rabbits. Br J Pharmacol, 104, 190-194.
|